This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2016 by Melissa J. Suter, Massachusetts General Hospital
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Melissa J. Suter, Massachusetts General Hospital Identifier:
First received: July 15, 2011
Last updated: March 14, 2016
Last verified: March 2016
This study will evaluate a new imaging technology, termed optical frequency domain imaging (OFDI) for detecting and diagnosing pulmonary malignancy in the central airways.

Squamous Cell Lung Cancer Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Resource links provided by NLM:

Further study details as provided by Melissa J. Suter, Massachusetts General Hospital:

Primary Outcome Measures:
  • Evaluation of imaging device [ Time Frame: on going ]

Estimated Enrollment: 30
Study Start Date: December 2008
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Detailed Description:

The prevalence and high mortality rate associated with lung squamous cell carcinoma and the lack of any widely accepted screening and surveillance tools, highlights the need for new imaging paradigms that will ultimately lead to a reduction in patient mortality.

Bronchial carcinoma-in-situ will progress to invasive cancer in over 40% of individuals, and although the progression occurs over a long period of time, the majority of carcinomas are detected in the later stages of disease development, offering patients only a slim chance of cure. Although significant effort in the development of screening paradigms for the detection of lung cancer in the central airways have been made, to date there is still no widely accepted and validated approach. Optical frequency domain imaging (OFDI) is a recent derivative of optical coherence tomography (OCT). OFDI can be used to conduct volumetric microscopy of the airways at a resolution comparable with architectural histopathology. The long term goal of this study is to use OFDI to screen the airways with the hope of detecting squamous cell carcinoma at an early more curable stage.

Standard of care bronchoscopy preparation and procedures will be followed including moderate sedation, pulse oximetry and blood pressure monitoring as per department protocol. A combination of currently approved bronchoscopy techniques including standard white light bronchoscopy, autofluorescence bronchoscopy, and narrow band imaging will be used to assess the airways. Bronchial regions of interest (ROI) suspected to be premalignant or malignant, will be imaged using the OFDI system and catheter prior to biopsy acquisition. It is anticipated that a minimum of 3 OFDI-biopsy correlated pairs from each study participant will be obtained. An additional OFDI and biopsy will be obtained from a normal ROI. It is expected that the experimental procedure will add less than 10 minutes to the total length of the bronchoscopy procedure, but a stopping rule will be instituted to ensure that the experimental procedure does not exceed 20 minutes.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients referred for bronchoscopy procedures in the Pulmonary and Critical Care Department at Massachusetts General Hospital for the evaluation of known or suspected pulmonary malignancy will be enrolled in this study. Study patients will receive standard of care for pulmonary disease consistent with national guidelines.

Inclusion Criteria:

  • Patients undergoing bronchoscopy for known or suspected pulmonary malignancy in the central airways
  • Patients must be over the age of 18
  • Patient must be able to give informed consent
  • Women with child bearing potential must have a negative pregnancy test the day before or the day of the procedure.

Exclusion Criteria:

- Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01396603

United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Melissa J Suter, PhD    617-724-7691   
Principal Investigator: Melissa J Suter, PhD         
Sub-Investigator: Colleen L Channick, MD         
Sponsors and Collaborators
Massachusetts General Hospital
National Cancer Institute (NCI)
Principal Investigator: Melissa J Suter, PhD Massachusetts General Hospital
  More Information

Responsible Party: Melissa J. Suter, Assistant Professor of Medicine, Massachusetts General Hospital Identifier: NCT01396603     History of Changes
Other Study ID Numbers: 2008P001254
R00CA134920 ( US NIH Grant/Contract Award Number )
Study First Received: July 15, 2011
Last Updated: March 14, 2016

Keywords provided by Melissa J. Suter, Massachusetts General Hospital:
Optical Frequency Domain Imaging
Optical Coherence Tomography
Optical biopsy
Comprehensive Microscopy

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases processed this record on June 23, 2017